Cell-based therapies for trabecular meshwork regeneration to treat glaucoma

19Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

Glaucoma is clinically characterized by elevated intraocular pressure (IOP) that leads to retinal ganglion cell (RGC) and optic nerve damage, and eventually blindness if left untreated. Even in normal pressure glaucoma patients, a reduction of IOP is currently the only effective way to pre-vent blindness, by either increasing aqueous humor outflow or decreasing aqueous humor produc-tion. The trabecular meshwork (TM) and the adjacent Schlemm’s canal inner wall play a key role in regulating IOP by providing resistance when aqueous humor drains through the tissue. TM dysfunction seen in glaucoma, through reduced cellularity, abnormal extracellular matrix accumula-tion, and increased stiffness, contributes to elevated IOP, but current therapies do not target the TM tissue. Stem cell transplantation for regeneration and re-functionalization of damaged TM has shown promise in providing a more direct and effective therapy for glaucoma. In this review, we describe the use of different types of stem cells for TM regeneration in glaucoma models, the mechanisms of regeneration, and the potential for glaucoma treatment using autologous stem cell trans-plantation.

Cite

CITATION STYLE

APA

Mallick, S., Sharma, M., Kumar, A., & Du, Y. (2021, September 1). Cell-based therapies for trabecular meshwork regeneration to treat glaucoma. Biomolecules. MDPI AG. https://doi.org/10.3390/biom11091258

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free